Making the jump from private to public markets can be an exciting endeavor, but you have to make sure your company is in the right position or you risk damaging your credibility on the Street. So how will you know when you’re ready? We’ve compiled a list of seven red flags to look out for that mean you’re not quite there. Remember, an IPO takes time and it pays to do your due diligence.
The Westwicke Blog is designed to deliver information and insights into the ever-changing world of investor relations and the capital markets, with a specific focus on the healthcare industry.
While most management teams tend to view investors as strictly institutional — professionals putting capital to work for mutual funds, hedge funds, family offices, asset managers, etc. — “retail investors,” individuals investing their personal capital, are continuing to become a bigger and more influential part of the investor landscape.
This emerging community of investors runs the gamut in terms of profile and motivation. They’re day-traders moving in and out of stocks on an everyday basis, individuals controlling the execution of their retirement funds, households investing for the future, true speculators looking for high-flying returns, and everyday people simply looking to generate extra cash.
Medical meetings allow analysts and investors to explore an array of public and private healthcare companies in one place and gain deeper insight into the industry’s competitive dynamics as they meet with management teams and learn about new products and strategies.
These and other industry events play an important role in enhancing Wall Street professionals’ understanding of the quickly changing healthcare landscape – helping them reinforce and update their investment ideas, conduct due diligence, evaluate new prospects, and spot emerging competitive threats.
As head of business development for Westwicke Partners, I always look forward to a jam-packed, action-filled week of conversations. This year did not disappoint.
With almost 50 meetings scheduled, I had the pleasure of meeting with many compelling private and public healthcare companies. And there was no shortage of innovation, grit, and creativity this year. I found many management teams determined to advance their science, technology, and businesses in 2018.
For public and mature private companies in need of financing, finding the right investment bank is a vital early step. Choose wrong, and your deal could sour, or you could wind up accepting an unfavorable valuation. But the right banker will guide you through your IPO, follow-on investment, or other financing deal while maintaining a long-term relationship with you that could bear fruit for years to come.
So what should you be looking for? For each investment bank you consider, you’ll want to look hard at three things above all: the quality of each firm’s banking team itself, the credibility of its research team, and the relationships that you can forge with its people, as well as their own relationships with the Street.
The last thing any company wants is disappointing news. But it’s more than likely that your company will experience a bump in the road from time to time. Don’t let the prospect of delivering bad news rattle you. Even the best managed companies can experience a “miss.”
How you communicate that miss can have a lasting impact. Thorough preparation and a well thought out action plan is the best way to ensure things go smoothly. I asked a few of my colleagues to share their advice for the best way to deliver bad news. Here’s what they said:
While it seems as though legislative uncertainty is increasingly an issue that the investment community needs to deal with on a year-round basis, at this time of year, many public companies in the healthcare sector are navigating the challenges of a “legislative overhang.”
With tax reform a key focus of President Trump’s legislative agenda, investors are keenly focused on how potential changes in healthcare policy may affect public companies’ growth and profitability profiles going forward. As always, heightened focus from investors means more questions for executive management teams; with legislative uncertainty however, there are no clean answers to these questions. So, what should you do?
Shareholders, investors, and analysts all have a unique set expectations and a well-thought-out investor relations strategy can help you balance these demands. Executing a successful strategy is essential to your company’s appeal and can help build credibility with Wall Street. We’ve compiled a list of the top 10 things you can do to drive your investor relations strategy and keep investors engaged in your company’s story.
One of the perennial issues during earnings season is setting a date for your quarterly financial release that doesn’t clash with a dozen or so of your peers. By choosing a date that’s too crowded, investor and analyst participation may be low. The same problem can happen when choosing a date for an R&D day or investor day. So how do you go about choosing a date for your event that doesn’t clash with everyone else’s?
The answer is you don’t. Or rather, you shouldn’t waste your time thinking too much about it. First, I’ll talk a little about why you shouldn’t overthink the matter, then I’ll address what you can do to combat low live participation on your call or at your event.
According to a report by Moody’s Investors Service earlier this year, passive investments account for 28.5% of assets under management in the U.S., a figure expected to exceed 50% in the next four to seven years.
What’s the driving force behind this passive investing trend? Passive funds – including ETFs, index funds, and quant funds – often have lower fees and superior performance over many actively managed, and more expensive, mutual funds. Passive investments may track indexes, such as the S&P 500, or be driven by computer-based models.